What Will Part D Prices Look Like in 2007?

Big Pharma companies say its too early to tell what prices will look like under Medicare Part D next year. That is in part because they can't be sure yet what prices they will get in 2006. That won't be clear until claims are reconciled this fall.

The question came up on almost all the Big Pharma company second quarter earnings calls: What will happen to prices under Medicare Part D in 2007? As has become abundantly clear, most pharma companies saw a net price increase from the transition to Part D this year, since more than six million Medicare beneficiaries previously receiving coverage under Medicaid (with mandatory rebates) transferred to the new program. (See "Big Pharma’s Secret Weapon," The RPM Report, July/August 2006 Also see "Big Pharma's Secret Weapon: Medicare Starts to Pay Off-Quietly" - Pink Sheet, 1 July, 2006..)

But what happens next year? Managed care plans offering Part D now have actual enrollment, and a handful of plans—led...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet

After Sarepta Reversed Course On Elevidys, Could An Adcomm Be Next?

 

One option for the FDA going forward could be holding an advisory committee meeting on its safety concerns after Sarepta agreed to stop all shipments of its DMD gene therapy.

Advocates Want New Bipartisan PBM Reform Package To Stand Alone

 
• By 

A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By 

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.